Samuel Rae

Samuel Rae

InvestorPlace Contributor

Samuel is a currency trader, equities analyst, author and contributor to a number of the leading financial market publications including Futures Magazine, FX Trader Magazine and Spreadbet Magazine. Born and educated in the U.K., he currently lives in Barcelona, Spain, with his two dogs, managing a personal portfolio of mid- to high-risk U.S. equities. He specializes in small- to mid-cap biotechnology, energy and mining stocks.

Recent Articles

3 Mobile Payment Companies JPMorgan Could Buy

By Samuel Rae, InvestorPlace Contributor

JPMorgan Chase (JPM) may've been outbid by Vantiv for Worldpay, but there are several other mobile payment companies it could buy.

3 Virtual Reality Stocks (That Aren’t Facebook or Sony)

By Samuel Rae, InvestorPlace Contributor

Virtual reality and augmented reality haven't taken off yet, but these three companies offer stronger pure plays than Facebook or Sony.

3 Pivotal Drug Trials to Watch for Explosive Potential

By Samuel Rae, InvestorPlace Contributor

Here's a look at three biotech stocks that have at least one treatment prepped to enter pivotal clinical trials soon.

4 Explosive Nevada Gold Mine Projects to Watch This Year

By Samuel Rae, InvestorPlace Contributor

When companies look for gold in America, they do it in Nevada. These four Nevada gold mine projects could be game-changers for the gold miners carrying them out.

Is Teva Pharmaceutical Industries Ltd (ADR) Stock a Migraine Buy?

By Samuel Rae, InvestorPlace Contributor

Teva's recent migraine drug data, while positive, didn't impress investors. What happened, and should you tussle with TEVA stock?

Load More